1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol | 110505-84-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol
• 英文别名: 1-(1H-indol-4-yloxy)-3-(2-phenylethylamino)propan-2-ol
• CAS: 110505-84-5
• 化学式: C₁₉H₂₂N₂O₂
• 分子量: 310.396
• InChiKey: MDPRLCKPDFRPJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  57.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基吲哚 在 1,4-二氧六环 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 58.0h， 生成 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol
  参考文献：
  名称：

  Synthesis and .beta.-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols

  摘要：

  Although (-)-[125I]iodopindolol (IPIN) can be used to label beta-adrenergic receptors in the central nervous system in vivo, use of this ligand for receptor imaging studies in humans may be limited due to its relatively poor penetration into the brain. As a first step toward the development of radioligands for imaging studies, we report the synthesis and measurement of in vitro binding affinity to beta-receptors of a series of 1-(substituted amino)-3-(4-indolyloxy)-propan-2-ol derivatives. The synthesized compounds vary widely in their lipophilicity as measured by their distribution coefficients between phosphate buffer and octanol at pH 7.4. The affinity of these compounds for beta-receptors, as measured by their inhibition of binding of IPIN to rat cortical and cerebellar membranes in vitro, ranges from 2- to 100-fold less potent than pindolol; the most potent compounds have Ki values of 2-5 nM. The radiolabeled analogues of some of these compounds may prove useful for receptor imaging studies.

  DOI：

  10.1021/jm00158a035

文献信息

• Treatment of sleep disorders
  申请人：ELI LILLY AND COMPANY

  公开号：EP0792649A1

  公开（公告）日：1997-09-03

  Disorders of sleep are treated with a combination of a serotonin reuptake inhibitor and a serotonin 1A receptor antagonist.

  睡眠障碍的治疗通常采用血清素再摄取抑制剂和血清素1A受体拮抗剂的联合使用。
• Potentiation of drug response by a serotonin 1A receptor antagonist
  申请人：ELI LILLY AND COMPANY

  公开号：EP0687472A2

  公开（公告）日：1995-12-20

  The power of fluoxetine, venlafaxine, milnacipran and duloxetine to increase the availability of serotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.

  氟西汀、文拉法辛、米那西普兰和度洛西汀在与血清素 1A 受体拮抗剂联合用药时，可增加血清素、去甲肾上腺素和多巴胺（尤其是血清素）的供应量。
• TEJANI-BUTT SH. M.; BRUNSWICK D. J., J. MED. CHEM., 29,(1986) N 8, 1524-1527
  作者：TEJANI-BUTT SH. M.、 BRUNSWICK D. J.

  DOI：——

  日期：——
• Potentiation of serotonin response
  申请人：ELI LILLY AND COMPANY

  公开号：EP0759299B1

  公开（公告）日：2000-04-26
• EP0642787A2
  申请人：——

  公开号：EP0642787A2

  公开（公告）日：1995-03-15